Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Primary Myelofibrosis 4Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Polycythemia Vera 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Leukemia 2Graft vs Host Disease 2Thrombocythemia, Essential 1Thalassemia 1Preleukemia 1Precancerous Conditions 1Neoplasms by Histologic Type 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Hematologic Diseases 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1Bone Marrow Diseases 1

Interventions

ibrutinib 2ruxolitinib 1asciminib 1Specimen Handling 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × ruxolitinib × 30 days × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡